Abstract

C Vogelberg has participated in an advisory board for Boehringer Ingelheim;

SJ Szefler has received personal fees from Aerocrine, Boehringer-Ingelheim, Daiichi Sankyo, Genentech, GlaxoSmithKline, Merck, Novartis, and Roche, and research grants from GlaxoSmithKline;

E Hamelmann has received research grants and other fees from Boehringer Ingelheim and non-financial support from Boehringer Ingelheim;

A Boner has nothing to disclose;

P Moroni-Zentgraf is an employee of Boehringer Ingelheim;

M Engel is an employee of Boehringer Ingelheim;

G El Azzi is an employee of Boehringer Ingelheim;

H Finnigan is an employee of Boehringer Ingelheim;

M Vandewalker has received research grants and personal fees from Boehringer Ingelheim.